JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Increased echogenicity of renal cortex: a transient feature in acutely ill children.

OBJECTIVE: The purpose of our study was to determine the frequency of hyperechogenicity of renal parenchyma in children with acute abdominal illness and to evaluate the assumed transient feature of this hyperechogenicity.

MATERIALS AND METHODS: Between January 2005 and February 2006, 189 consecutive patients (112 boys and 77 girls; mean age, 10 years) presenting with acute abdominal pain were examined with sonography. Patients with a known history of renal disease and those with acute urinary tract infection were excluded from the study. Echogenicity of the renal cortex in comparison with adjacent liver was recorded. Renal cortex echogenicity was divided into three groups; group 1, renal cortex echogenicity less than liver parenchyma echogenicity; group 2, renal cortex echogenicity similar to that of liver parenchyma; and group 3, renal cortex echogenicity greater than that of liver parenchyma. Patients with hyperechogenicity were reexamined with sonography after 2 weeks or more. The final sonographic diagnosis and clinical outcome were noted.

RESULTS: Renal cortex echogenicity was equal to or greater than that of the liver parenchyma in 18% (n = 34) of 189 patients. Increased echogenicity of the renal cortex returned to normal in 2 or more weeks in all patients. Three patients had no follow-up. Clinical diagnoses were idiopathic acute abdominal pain (n = 74), appendicitis (n = 83), mesenteric lymphadenitis (n = 15), ileocecitis (n = 7), gastroenteritis (n = 7), Crohn's disease (n = 1), intussusception (n = 1), and pneumonia (n = 1). No concurrent renal disease was diagnosed.

CONCLUSION: Increased echogenicity of renal parenchyma in children with acute illness is a transient feature and does not necessarily indicate renal disease.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app